Here's how LINK.SPRINGER.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

LINK . SPRINGER . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Link.springer.com Make Money
  6. Keywords
  7. Topics
  8. Schema
  9. External Links
  10. Analytics And Tracking
  11. Libraries
  12. CDN Services

We are analyzing https://link.springer.com/article/10.1186/s12943-020-1130-z.

Title:
Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness | Molecular Cancer
Description:
Background Ovarian cancer is one of the most common and malignant cancers, partly due to its late diagnosis and high recurrence. Chemotherapy resistance has been linked to poor prognosis and is believed to be linked to the cancer stem cell (CSC) pool. Therefore, elucidating the molecular mechanisms mediating therapy resistance is essential to finding new targets for therapy-resistant tumors. Methods shRNA depletion of MYPT1 in ovarian cancer cell lines, miRNA overexpression, RT-qPCR analysis, patient tumor samples, cell line- and tumorsphere-derived xenografts, in vitro and in vivo treatments, analysis of data from ovarian tumors in public transcriptomic patient databases and in-house patient cohorts. Results We show that MYPT1 (PPP1R12A), encoding myosin phosphatase target subunit 1, is downregulated in ovarian tumors, leading to reduced survival and increased tumorigenesis, as well as resistance to platinum-based therapy. Similarly, overexpression of miR-30b targeting MYPT1 results in enhanced CSC-like properties in ovarian tumor cells and is connected to the activation of the Hippo pathway. Inhibition of the Hippo pathway transcriptional co-activator YAP suppresses the resistance to platinum-based therapy induced by either low MYPT1 expression or miR-30b overexpression, both in vitro and in vivo. Conclusions Our work provides a functional link between the resistance to chemotherapy in ovarian tumors and the increase in the CSC pool that results from the activation of the Hippo pathway target genes upon MYPT1 downregulation. Combination therapy with cisplatin and YAP inhibitors suppresses MYPT1-induced resistance, demonstrating the possibility of using this treatment in patients with low MYPT1 expression, who are likely to be resistant to platinum-based therapy.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

  • Science
  • Education
  • Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💾}

We see no obvious way the site makes money.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

mypt, cells, cancer, expression, ovarian, hippo, tumor, pathway, fig, pubmed, mirb, article, resistance, skov, cell, levels, google, scholar, yap, patients, ovcar, cas, additional, downregulation, file, survival, shmypt, data, tumors, treatment, figure, genes, cisplatin, expressing, analyzed, gene, found, therapy, target, tumorspheres, results, central, samples, patient, increased, stemness, low, growth, xenografts, showed,

Topics {✒}

mypt1/c-jun/vegfa pathway fluorescence-activated cell sorting article download pdf kaplan-meier plots showing net/projects/mev-tm4/ feed-back loop enhancing article muñoz-galvån yap-dependent matrix remodelling phospho-nf2/total nf2 compared renewing tumor-initiating cells enhanced stem-cell properties microrna-30d promotes angiogenesis mir-30b-expressing cells ev-expressing cells independently mypt1-depleted skov3-derived tumors mir-30b expression lead universidad de sevilla ev-expressing cells compared mir-30b-mypt1 axis empty vector-expressing cells lats1/warts phosphorylates mypt1 ilk phosphorylates mypt1-pp1 ovcar8-derived xenografts grew hippo signaling-pathway components mir-30b-expressing es-2 platinum-based therapy induced shmypt1-expressing skov3 cells consejeria de salud mir-30b expression levels mir-30b expression led advanced ovarian cancers paraffin-embedded tissue samples higher mir-30b expression ibis/huvr ethical committee mir-30b expression level myosin-binding subunit human ovarian cancer plan estatal de privacy choices/manage cookies western blot showing ovarian cell lines term enrichment analyses ministerio de ciencia ciber de cåncer junta de andalucia molecular mechanism connecting ovarian cancer stem cancer stem cell epithelial ovarian cancer platinum-sensitive ovarian tumors

Schema {đŸ—ș}

WebPage:
      mainEntity:
         headline:Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness
         description:Ovarian cancer is one of the most common and malignant cancers, partly due to its late diagnosis and high recurrence. Chemotherapy resistance has been linked to poor prognosis and is believed to be linked to the cancer stem cell (CSC) pool. Therefore, elucidating the molecular mechanisms mediating therapy resistance is essential to finding new targets for therapy-resistant tumors. shRNA depletion of MYPT1 in ovarian cancer cell lines, miRNA overexpression, RT-qPCR analysis, patient tumor samples, cell line- and tumorsphere-derived xenografts, in vitro and in vivo treatments, analysis of data from ovarian tumors in public transcriptomic patient databases and in-house patient cohorts. We show that MYPT1 (PPP1R12A), encoding myosin phosphatase target subunit 1, is downregulated in ovarian tumors, leading to reduced survival and increased tumorigenesis, as well as resistance to platinum-based therapy. Similarly, overexpression of miR-30b targeting MYPT1 results in enhanced CSC-like properties in ovarian tumor cells and is connected to the activation of the Hippo pathway. Inhibition of the Hippo pathway transcriptional co-activator YAP suppresses the resistance to platinum-based therapy induced by either low MYPT1 expression or miR-30b overexpression, both in vitro and in vivo. Our work provides a functional link between the resistance to chemotherapy in ovarian tumors and the increase in the CSC pool that results from the activation of the Hippo pathway target genes upon MYPT1 downregulation. Combination therapy with cisplatin and YAP inhibitors suppresses MYPT1-induced resistance, demonstrating the possibility of using this treatment in patients with low MYPT1 expression, who are likely to be resistant to platinum-based therapy.
         datePublished:2020-01-11T00:00:00Z
         dateModified:2020-01-11T00:00:00Z
         pageStart:1
         pageEnd:16
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s12943-020-1130-z
         keywords:
            Ovarian cancer
            MYPT1 (PPP1R12A)
            miR-30b
            Therapy resistance
            Hippo pathway
            Stemness
            Cancer Research
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-020-1130-z/MediaObjects/12943_2020_1130_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-020-1130-z/MediaObjects/12943_2020_1130_Fig2_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-020-1130-z/MediaObjects/12943_2020_1130_Fig3_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-020-1130-z/MediaObjects/12943_2020_1130_Fig4_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-020-1130-z/MediaObjects/12943_2020_1130_Fig5_HTML.png
         isPartOf:
            name:Molecular Cancer
            issn:
               1476-4598
            volumeNumber:19
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Sandra Muñoz-GalvĂĄn
               affiliation:
                     name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
                     address:
                        name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
                        type:PostalAddress
                     type:Organization
                     name:CIBERONC, Instituto de Salud Carlos III
                     address:
                        name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Blanca Felipe-Abrio
               affiliation:
                     name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
                     address:
                        name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
                        type:PostalAddress
                     type:Organization
                     name:CIBERONC, Instituto de Salud Carlos III
                     address:
                        name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Eva M. Verdugo-Sivianes
               affiliation:
                     name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
                     address:
                        name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
                        type:PostalAddress
                     type:Organization
                     name:CIBERONC, Instituto de Salud Carlos III
                     address:
                        name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Marco Perez
               affiliation:
                     name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
                     address:
                        name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
                        type:PostalAddress
                     type:Organization
                     name:CIBERONC, Instituto de Salud Carlos III
                     address:
                        name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Manuel P. JimĂ©nez-GarcĂ­a
               affiliation:
                     name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
                     address:
                        name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
                        type:PostalAddress
                     type:Organization
                     name:CIBERONC, Instituto de Salud Carlos III
                     address:
                        name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Elisa Suarez-Martinez
               affiliation:
                     name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
                     address:
                        name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
                        type:PostalAddress
                     type:Organization
                     name:CIBERONC, Instituto de Salud Carlos III
                     address:
                        name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Purificacion Estevez-Garcia
               affiliation:
                     name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
                     address:
                        name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
                        type:PostalAddress
                     type:Organization
                     name:CIBERONC, Instituto de Salud Carlos III
                     address:
                        name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Amancio Carnero
               url:http://orcid.org/0000-0003-4357-3979
               affiliation:
                     name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
                     address:
                        name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
                        type:PostalAddress
                     type:Organization
                     name:CIBERONC, Instituto de Salud Carlos III
                     address:
                        name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Downregulation of MYPT1 increases tumor resistance in ovarian cancer by targeting the Hippo pathway and increasing the stemness
      description:Ovarian cancer is one of the most common and malignant cancers, partly due to its late diagnosis and high recurrence. Chemotherapy resistance has been linked to poor prognosis and is believed to be linked to the cancer stem cell (CSC) pool. Therefore, elucidating the molecular mechanisms mediating therapy resistance is essential to finding new targets for therapy-resistant tumors. shRNA depletion of MYPT1 in ovarian cancer cell lines, miRNA overexpression, RT-qPCR analysis, patient tumor samples, cell line- and tumorsphere-derived xenografts, in vitro and in vivo treatments, analysis of data from ovarian tumors in public transcriptomic patient databases and in-house patient cohorts. We show that MYPT1 (PPP1R12A), encoding myosin phosphatase target subunit 1, is downregulated in ovarian tumors, leading to reduced survival and increased tumorigenesis, as well as resistance to platinum-based therapy. Similarly, overexpression of miR-30b targeting MYPT1 results in enhanced CSC-like properties in ovarian tumor cells and is connected to the activation of the Hippo pathway. Inhibition of the Hippo pathway transcriptional co-activator YAP suppresses the resistance to platinum-based therapy induced by either low MYPT1 expression or miR-30b overexpression, both in vitro and in vivo. Our work provides a functional link between the resistance to chemotherapy in ovarian tumors and the increase in the CSC pool that results from the activation of the Hippo pathway target genes upon MYPT1 downregulation. Combination therapy with cisplatin and YAP inhibitors suppresses MYPT1-induced resistance, demonstrating the possibility of using this treatment in patients with low MYPT1 expression, who are likely to be resistant to platinum-based therapy.
      datePublished:2020-01-11T00:00:00Z
      dateModified:2020-01-11T00:00:00Z
      pageStart:1
      pageEnd:16
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s12943-020-1130-z
      keywords:
         Ovarian cancer
         MYPT1 (PPP1R12A)
         miR-30b
         Therapy resistance
         Hippo pathway
         Stemness
         Cancer Research
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-020-1130-z/MediaObjects/12943_2020_1130_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-020-1130-z/MediaObjects/12943_2020_1130_Fig2_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-020-1130-z/MediaObjects/12943_2020_1130_Fig3_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-020-1130-z/MediaObjects/12943_2020_1130_Fig4_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs12943-020-1130-z/MediaObjects/12943_2020_1130_Fig5_HTML.png
      isPartOf:
         name:Molecular Cancer
         issn:
            1476-4598
         volumeNumber:19
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Sandra Muñoz-GalvĂĄn
            affiliation:
                  name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
                  address:
                     name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
                     type:PostalAddress
                  type:Organization
                  name:CIBERONC, Instituto de Salud Carlos III
                  address:
                     name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Blanca Felipe-Abrio
            affiliation:
                  name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
                  address:
                     name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
                     type:PostalAddress
                  type:Organization
                  name:CIBERONC, Instituto de Salud Carlos III
                  address:
                     name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Eva M. Verdugo-Sivianes
            affiliation:
                  name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
                  address:
                     name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
                     type:PostalAddress
                  type:Organization
                  name:CIBERONC, Instituto de Salud Carlos III
                  address:
                     name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Marco Perez
            affiliation:
                  name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
                  address:
                     name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
                     type:PostalAddress
                  type:Organization
                  name:CIBERONC, Instituto de Salud Carlos III
                  address:
                     name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Manuel P. JimĂ©nez-GarcĂ­a
            affiliation:
                  name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
                  address:
                     name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
                     type:PostalAddress
                  type:Organization
                  name:CIBERONC, Instituto de Salud Carlos III
                  address:
                     name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Elisa Suarez-Martinez
            affiliation:
                  name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
                  address:
                     name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
                     type:PostalAddress
                  type:Organization
                  name:CIBERONC, Instituto de Salud Carlos III
                  address:
                     name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Purificacion Estevez-Garcia
            affiliation:
                  name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
                  address:
                     name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
                     type:PostalAddress
                  type:Organization
                  name:CIBERONC, Instituto de Salud Carlos III
                  address:
                     name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Amancio Carnero
            url:http://orcid.org/0000-0003-4357-3979
            affiliation:
                  name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
                  address:
                     name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
                     type:PostalAddress
                  type:Organization
                  name:CIBERONC, Instituto de Salud Carlos III
                  address:
                     name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Molecular Cancer
      issn:
         1476-4598
      volumeNumber:19
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
      address:
         name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
         type:PostalAddress
      name:CIBERONC, Instituto de Salud Carlos III
      address:
         name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
         type:PostalAddress
      name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
      address:
         name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
         type:PostalAddress
      name:CIBERONC, Instituto de Salud Carlos III
      address:
         name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
         type:PostalAddress
      name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
      address:
         name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
         type:PostalAddress
      name:CIBERONC, Instituto de Salud Carlos III
      address:
         name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
         type:PostalAddress
      name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
      address:
         name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
         type:PostalAddress
      name:CIBERONC, Instituto de Salud Carlos III
      address:
         name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
         type:PostalAddress
      name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
      address:
         name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
         type:PostalAddress
      name:CIBERONC, Instituto de Salud Carlos III
      address:
         name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
         type:PostalAddress
      name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
      address:
         name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
         type:PostalAddress
      name:CIBERONC, Instituto de Salud Carlos III
      address:
         name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
         type:PostalAddress
      name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
      address:
         name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
         type:PostalAddress
      name:CIBERONC, Instituto de Salud Carlos III
      address:
         name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
         type:PostalAddress
      name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
      address:
         name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
         type:PostalAddress
      name:CIBERONC, Instituto de Salud Carlos III
      address:
         name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Sandra Muñoz-GalvĂĄn
      affiliation:
            name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
            address:
               name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
               type:PostalAddress
            type:Organization
            name:CIBERONC, Instituto de Salud Carlos III
            address:
               name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
               type:PostalAddress
            type:Organization
      name:Blanca Felipe-Abrio
      affiliation:
            name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
            address:
               name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
               type:PostalAddress
            type:Organization
            name:CIBERONC, Instituto de Salud Carlos III
            address:
               name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
               type:PostalAddress
            type:Organization
      name:Eva M. Verdugo-Sivianes
      affiliation:
            name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
            address:
               name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
               type:PostalAddress
            type:Organization
            name:CIBERONC, Instituto de Salud Carlos III
            address:
               name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
               type:PostalAddress
            type:Organization
      name:Marco Perez
      affiliation:
            name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
            address:
               name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
               type:PostalAddress
            type:Organization
            name:CIBERONC, Instituto de Salud Carlos III
            address:
               name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
               type:PostalAddress
            type:Organization
      name:Manuel P. JimĂ©nez-GarcĂ­a
      affiliation:
            name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
            address:
               name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
               type:PostalAddress
            type:Organization
            name:CIBERONC, Instituto de Salud Carlos III
            address:
               name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
               type:PostalAddress
            type:Organization
      name:Elisa Suarez-Martinez
      affiliation:
            name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
            address:
               name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
               type:PostalAddress
            type:Organization
            name:CIBERONC, Instituto de Salud Carlos III
            address:
               name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
               type:PostalAddress
            type:Organization
      name:Purificacion Estevez-Garcia
      affiliation:
            name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
            address:
               name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
               type:PostalAddress
            type:Organization
            name:CIBERONC, Instituto de Salud Carlos III
            address:
               name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
               type:PostalAddress
            type:Organization
      name:Amancio Carnero
      url:http://orcid.org/0000-0003-4357-3979
      affiliation:
            name:Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas
            address:
               name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
               type:PostalAddress
            type:Organization
            name:CIBERONC, Instituto de Salud Carlos III
            address:
               name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
      name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
      name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
      name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
      name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
      name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
      name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
      name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
      name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
      name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
      name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
      name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
      name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
      name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain
      name:Instituto de Biomedicina de Sevilla, IBIS, Hospital Universitario Virgen del RocĂ­o, Universidad de Sevilla, Consejo Superior de Investigaciones CientĂ­ficas, Seville, Spain
      name:CIBERONC, Instituto de Salud Carlos III, Madrid, Spain

External Links {🔗}(213)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Clipboard.js
  • Prism.js

CDN Services {📩}

  • Crossref

5.04s.